VivoSeq
Oncology

Lung Neoplasm Malignant

11

Pipeline Programs↗

1

Active Trials↗

7

Companies Involved↗

Lung Neoplasm Malignant is an emerging landscape with 11 programs across 7 companies. The most active players are Merck & Co., McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Johnson & Johnson.

Intelligence

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

0/100

Mech. Concentration

17/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

5 programs

Phase 2M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 2Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2G

Gynecologic Oncology Group

1 program

Phase 2K

Kenvue Brands

1 program

Phase 2A

Avyxa

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

82%

Small molecule

9 of 11 classified programs — the dominant modality here.

18%ALL OTHERSMonoclonal antibody19%Antibody–drug conjugate19%

Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 92% of 12 pipeline programs.

Analysis

Trial Status

1

clinical trials

Recruiting1 · 100%

Clinical Trials

Trial Activity

KEYMAKER-U01 Substudy 01E: A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)
Recruiting·Merck & Co. logoMerck & Co.·Phase 2·NCT06788912·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)